DURHAM, N.C., July 29, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2025 before the market opens on Wednesday, August 6, 2025. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-800-715- ...

Conference Call Scheduled for August 5th at 8:30 AM ETNEWBURYPORT, Mass., July 29, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ: UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today announced the Company plans to report financial results for the second quarter ended June 30, 2025 on August 4, 2025 after the market close. The Company will hold a conference call to discuss results the following day, August 5th, at 8:30 ...

公司核心观点 - 全球领先的外周神经功能修复创新手术解决方案开发商和营销商Axogen公司宣布管理层将于2025年8月12日参加Canaccord Genuity第45届年度增长会议的一对一投资者会议 [1] 公司介绍 - Axogen专注于外周神经再生和修复技术的科学研究、开发和商业化 [2] - 公司员工致力于为外科医生和医疗服务提供者提供创新、经临床验证且经济有效的修复解决方案，帮助因外周神经受损或横断的患者恢复外周神经功能和生活质量 [2] 行业背景 - 外周神经为身体的运动和感觉信号提供通路，人们每天都会遭受影响外周神经功能的创伤性损伤或进行相关手术，外周神经受损或无法正确重新连接会导致肌肉或器官功能丧失、感觉丧失或引发疼痛 [2] 公司产品应用 - 公司的外周神经修复平台产品广泛应用于创伤性损伤、口腔颌面外科、乳房重建和疼痛外科治疗等领域，涵盖计划手术和紧急手术 [2] - 计划手术通常由寻求缓解神经缺损或先前手术干预导致病症的患者进行，如乳房重建、神经瘤切除后的神经重建、口腔颌面手术和神经减压等 [2] - 紧急手术通常源于最初在急诊室出现的损伤，专家会在损伤后立即或几天内进行干预 [2] 公司产品组合 - 公司的外周神经修复平台拥有全面的产品组合，包括Avance Nerve Graft®、Axoguard Nerve Connector®、Axoguard Nerve Protector®、Axoguard HA+ Nerve Protector™、Avive+ Soft Tissue Matrix™和Axoguard Nerve Cap®等 [2] 公司市场范围 - 公司产品在美国、加拿大、英国、韩国以及其他一些欧洲和国际市场均有销售 [2]

SUNNYVALE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Canaccord Genuity 45th Annual Growth Conference. The presentation will take place on Tuesday, August 12, 2025, at 11:00 a.m. Pacific Standard Time / 2:00 p.m. Eastern Standard Time. Event: Canac ...

MOUNTAIN VIEW, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the second quarter of 2025 after market close on Tuesday, August 12, 2025. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Investors interested in listening to the conference call may do so by ac ...

REDWOOD CITY, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the company will be presenting at the Canaccord Genuity 45th Annual Growth Conference in Boston on Tuesday, August 12, 2025, at 7:00 AM PT / 10:00 AM ET. A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/. About P ...

MOUNTAIN VIEW, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the second quarter 2025 and provide a business update after the close of trading on Tuesday, August 12, 2025. The Company’s management team will host a corresponding conference ca ...

ALAMEDA, Calif., July 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2025. Revenue of $339.5 million in the second quarter of 2025, an increase of 13.4% or 12.7% in constant currency1, compared to the second quarter of 2024. U.S. Thrombectomy revenue of $188.5 million in the second quarter of 2025, an increase of 22.6% compared to the second quarter of 2024. U.S. VTE revenue increased 42% c ...

财务表现 - 2025年第二季度GAAP收入达375亿美元，超出分析师预期32%，但同比下滑02% [1][5] - 非GAAP每股收益054美元，低于预期的058美元，同比下滑182% [1][2] - 调整后EBITDA为459亿美元，同比下滑80%，EBITDA利润率降至122%，同比下滑83个百分点 [2][6] - 净利润(GAAP)暴跌975%至50万美元，主要受189亿美元未实现外汇损失影响 [2][6] 业务构成 - 核心业务为汽车及医疗市场的热管理与气动舒适技术，产品包括气候控制座椅、座椅加热器、按摩解决方案等 [3] - 汽车气候与舒适解决方案收入308亿美元，同比增长38%，其中腰部按摩产品增长145%，电子产品增长421% [5] - 医疗业务收入112亿美元，同比下滑38%，占比较小但被视为长期多元化方向 [8][9] 运营亮点 - 获得62亿美元新汽车业务订单，包括福特下一代F系列平台合同及PulsA™按摩技术产品 [7] - 研发投入同比增长32%至226亿美元，销售及行政费用仅增长43% [6] - 毛利率(GAAP)下降18个百分点至239%，受原材料成本、劳动力成本及产品结构影响 [6] 战略方向 - 重点发展ClimateSense®和ComfortScale™等专利技术平台，提升电动车能效与舒适性 [4] - 优化全球制造布局，同时拓展医疗领域技术转化应用 [4][8] - 全年收入指引调整为143-15亿美元，EBITDA利润率目标117%-125%，资本支出下调至55-65亿美元 [10] 行业趋势 - 汽车行业对舒适性及能效解决方案需求持续增长，尤其电动车平台 [4][11] - 亚洲汽车市场疲软及汇率波动构成短期挑战，医疗业务提供长期多元化潜力 [11]

The Procedure Utilized Monogram’s mBôs TKA System Performed in India with Shalby Hospitals Groundbreaking Procedure Delivers the World’s First Autonomous Saw-Based Robotic TKA Surgery on a Live Patient AUSTIN, Texas, July 29, 2025 (GLOBE NEWSWIRE) -- Monogram Technologies Inc. (NASDAQ: MGRM) ("Monogram" or the "Company"), an AI-driven robotics company revolutionizing orthopedic surgery, today announced that on Saturday, July 26, 2025, Monogram completed the first ever fully autonomous saw-based robotic knee ...